Eledon Pharmaceuticals, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 28, 2024. This is an annual report, not a standalone fourth-quarter report.
Business context
Eledon is a clinical-stage biotechnology company with no approved products and no product-sales revenue. Its lead candidate, tegoprubart, is an anti-CD40L antibody being developed primarily to prevent kidney transplant rejection, with additional potential applications in xenotransplantation and ALS. The company has no commercial operations or product margins to report.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $30.3 million | $27.1 million |
| General and administrative expense | $12.7 million | $12.7 million |
| Total operating expenses | $43.0 million | $88.4 million |
| Net loss | $40.3 million | $88.0 million |
| Net loss per share, basic and diluted | $1.64 | $6.16 |
| Cash used in operating activities | $39.5 million | $28.4 million |
At December 31, 2023, cash and cash equivalents were $4.6 million and short-term investments were $46.5 million, totaling approximately $51.1 million. Working capital was $52.2 million; total liabilities were $5.6 million. The company reported no credit facility or committed funding source and no material debt disclosed in the supplied filing text.
Net cash used in investing activities was $45.3 million, primarily reflecting purchases of $78.3 million in short-term investments, partly offset by $33.0 million of maturities. Financing activities provided $33.0 million net, from the May 2023 private placement. The company reported an accumulated deficit of $243.2 million.
Changes versus FY2022
- Net loss narrowed by $47.6 million, mainly because FY2022 included a $48.6 million goodwill impairment; no impairment was recorded in FY2023.
- Research and development expense rose $3.2 million, principally due to higher clinical-trial and personnel costs, partly offset by lower stock-based compensation and manufacturing costs.
- Operating cash use increased by $11.1 million. The decline in cash and cash equivalents largely reflects purchases of short-term investments, rather than operating cash use alone.
- Other income increased to $2.7 million from $0.5 million, primarily due to higher interest income.
- The May 2023 private placement increased common shares outstanding to 24.2 million at year-end from 13.8 million a year earlier, before considering potential warrant exercises or later issuances.
Programs, outlook and material risks
- Kidney transplantation: The Phase 1b study had 11 participants in the November 2023 update. The company reported tegoprubart was generally safe and well tolerated, with one mild, treated rejection event and no graft loss or deaths; aggregate mean eGFR was above 70 mL/min/1.73m² at reported time points after day 90. The Phase 2 BESTOW trial dosed its first participant in August 2023 and is planned to enroll 120 participants, comparing tegoprubart with tacrolimus. The first participant entered a long-term open-label extension in October 2023.
- ALS: The company reported positive topline Phase 2a safety and tolerability results in 2022, but says further clinical development cannot continue without additional, ALS-specific financing. No assurance of such financing is given.
- Portfolio changes: The company prioritized kidney transplantation in January 2023 and discontinued its company-funded islet-cell transplantation and IgA nephropathy programs. In January 2024, tegoprubart was to be supplied, but not funded, for an investigator-initiated islet-transplant pilot study. Eledon also has a non-exclusive xenotransplant research collaboration with eGenesis.
- Going concern: Management and the independent auditor state that substantial doubt exists about the company’s ability to continue as a going concern for at least the next 12 months after issuance of the financial statements. The company expects continuing losses and requires additional capital.
- Contingent financing and dilution: The 2023 private placement raised $35.0 million gross ($33.0 million net) at its initial closing. Up to a further $105.0 million depends on specified clinical milestones and trading-price/volume conditions; up to $45.5 million more depends on exercise of initial-closing common warrants. Neither amount is assured. The filing reports substantial potential dilution from warrants, preferred-stock conversions, and possible later closings.
- Other risks: Tegoprubart remains investigational; clinical, regulatory, enrollment, manufacturing, competitive, reimbursement, intellectual-property, cybersecurity and capital-raising risks could delay or prevent development. The company relies on third parties for manufacturing and clinical operations. No material legal proceedings or accrued contingent liabilities were reported.
- Outlook: No quantified revenue, earnings, cash-flow or clinical guidance is provided. Management expects continued losses and increased expenses as development proceeds, subject to available financing.
Key facts investors should verify
- Current cash, investment balances, operating burn and runway, including any financing or cash use after December 31, 2023.
- Whether the private-placement milestone and trading conditions for the second and third closings are met, and whether warrants are exercised; assess resulting dilution.
- Updated BESTOW enrollment, safety, eGFR and rejection data, and the timing and funding for subsequent studies.
- Whether dedicated financing is secured for ALS development and whether the program resumes.
- Any changes in clinical, regulatory, manufacturing or competitive developments that could affect the $32.4 million in-process research and development asset.